iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
United Healthcare Criteria for Harvoni
 
 
  United Healthcare Criteria for Harvoni - Click Here .....8, 12 & 24 Weeks
 
Download the PDF here
 
Effective Date 10/15/2014
 
Background:
 
Harvoni™ (ledipasvir/sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.1

Treatment .gif

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org